中草药相关肝损伤的物质基础及其毒性机制OA北大核心CSTPCD
The material basis and toxic mechanism of herb-induced liver injury
中草药相关肝损伤的毒性物质基础及其毒性机制复杂,影响中药的安全应用.本文对中草药引起肝损伤的主要毒性成分及其作用机制进行了归纳分析,中草药肝损伤毒性成分可以分为药源性与非药源性两大类,药源性毒性成分主要有生物碱类、萜类、蒽醌类以及苯丙素类化合物,作用机制涉及氧化应激、细胞凋亡与坏死、CYP450酶、基因毒性等.非药源性物质主要有农药残留、二氧化硫残留、重金属、真菌、植物生长调节剂,机制涉及氧化应激、凋亡、代谢紊乱、CYP450酶等.在此基础上进一步提出了目前待解决的问题与研究难点,以期促进中草药肝毒性的基础研究.
Herb-induced liver injury(HILI)tends to have complex toxic material basis and toxic mechanism,which greatly affects the safety of traditional Chinese medicine.This article summarizes the main toxic components of Chinese herbal medicine causing liver injury and their mechanism of action.The toxic components of Chinese herbal medicine causing liver injury can be classified into two categories of drug-derived and non-drug-derived toxic components.Drug-derived toxic components mainly include alkaloids,terpenoids,anthraquinones,and phenylpropanoids,and their mechanism of action involves oxidative stress,apoptosis and necrosis,CYP450 enzymes,and genotoxicity.Non-drug-derived toxic components mainly include pesticide residues,sulfur dioxide residues,heavy metals,fungi,and plant growth regulators,and their mechanisms involve oxidative stress,apoptosis,metabolic disorders,and CYP450 enzymes.On this basis,this article further proposes the unsolved problems and research difficulties,in order to promote the basic research on the hepatotoxicity of traditional Chinese medicine.
刘雪莹;师荟荟;王浩文;杨涛
上海中医药大学附属曙光医院心血管研究室,上海 201203上海中医药大学附属曙光医院心血管研究室,上海 201203||上海市中医临床重点实验室,上海 201203
中草药化学性与药物性肝损伤物质基础
Drugs,Chinese HerbalChemical and Drug Induced Liver InjuryMaterial Basis
《临床肝胆病杂志》 2024 (008)
1512-1518 / 7
国家中医药管理局高水平中医药重点学科建设项目(zyyzdxk-2023060);上海市中医药事业发展三年行动计划[ZY(2018-2020)-CCCX-5001];上海市科学技术委员会科技创新行动计划医学创新研究专项(20Z21900100);上海市临床重点专科建设项目(shslczdzk01201) High-level Key Discipline Construction Project from State Administration of Traditional Chinese Medicine of China(zyyzdxk-2023060);Shanghai TCM Development Three-Year Action Plan Project[ZY(2018-2020)-CCCX-5001];Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project(20Z21900100);Shanghai Key Specialty of Traditional Chinese Clinical Medicine(shslczdzk01201)
评论